logo
calendar7 Oktabr 2022
view26
Main language:English

SPATIAL STRUCTURE OF (+)-1,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO-[3,4-b]INDOLE-1-ACETIC ACID

Field of Science:
pdf

633fb99857c58.pdf

PDF

ARTICLE ANNOTATION

quote
Background.An important problem of modern science in Uzbekistan is the integration of science and industry. In the field of chemical science, the creation of new pharmacologically active compounds is becoming urgent in order to ensure in theinternal market in the future plan original medicines of domestic production. Another direction is the introduction of existing drugs in domestic production, the socalled generics. In addition, improving the qualityand purity of these drugs is gradually moving intothe foreground. The obtaining of more exact characteristics of already known substances has its rightful place. Purpose. The purpose of the current investigation was study of spatial structure of drug etodolac with improved X-ray structural characteristics. Methodology.X-ray structural data were obtained at 293 K on anXcalibur R Oxford Diffraction automated diffractometer (Cu Ka radiation, k = 1.54184 Å, ω-scan mode, graphite monochromator). It was done comparative analysis obtained and previously published data. Originality. Although other authors previously published the structural characteristics of etodolac, we were able to obtain more accurate data on its spatial structure. At the same time, a twofold increase in the R-factor was achieved. Findings.At the same time, the accuracy of determining the spatial locations of all atoms inside the crystal lattice, torsion angles, interatomic distances, etc. have been almost doubled. Highlights: - the spatial structure of the anti-inflammatory drugetodolac was obtained by an improved R-factor.

AUTHORS

Tags

# рентгеноструктурный анализ# рентген тузилиш таҳлили# этодолак# улучшенный R-фактор# яхшиланган R-омил# X-ray crystal structure# improved R-factor# comparison.  etodolac

OTHER ARTICLES IN THIS JOURNAL

Rate Article

0
0 ratings
5
4
3
2
1

Article Identifiers

References

S.K. Sevinch, O. Orun, P.M. Tiber, P.Chilka-Suzgun,S.G. Kuchukguzel. Anti-cancer activity of etodolac and its derivatives on prostate and colorectal cancer cell lines. Proceedings 2018, 2, 1573. DOI: 10.3390/proceedings2251573.

R.L. Dreiser. A comparison of the efficacy of etodolac SR and etodolac in patients with rheumatoid arthritis or osteoarthritis. Rheumatol. Int. 1993, 13(Suppl 2), 13-18. https://doi.org/10.1007/BF00290279.

B.N. Coskun, B. Yagiz, Y. Pehlivan, E. Dalkilic. Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. Rheumatol. Int. 2019. https://doi.org/10.1007/s00296-019-04434-1.

British Pharmacopoeia, 2004.

K.P. Shah, K.Gumbhir-Shah, H.G. Brittain. Etodolac.Analitical profiles of drug substances and excipients 2002, 29, 105-147.

A.A. Gouda, M.I. Kotb El-Sayed, A.S. Amin, R. El-Sheikh. Spectrophotometric and spectrofluorometric methods for the determination of non-steroidal anti-inflammatory drugs: A review. Arabian J. Chem. -2013. -6. –P. 145-163.

Y. Jin, J. Zhao, L. Rhyman, P. Ramasami, Y. Shin, K.M. Jeong, J. Lee. Ultrasound-assisted chiral derivatization of etodolac with (1R)-(-)-menthyl chloroformate for the determination of etodolac enantiomers. Arabian J. Chem. -2016. -9. –P. 1962-1972.

CrysAlisPro. Ver. 1.171.33.40, UK: Oxford Diffraction, 2007.

G.M. Sheldrick, Acta Crystallogr. A 46 (1990) 467.

G.M. Sheldrick, SHELXS97, SHELXL97, Programs for Crystal Structures Solution and Refinement, University of Göttingen, Göttingen, Germany, 1997.

X.P. Siemens, Molecular Graphics Program. Version 5.03, Siemens Analytical X-Ray Instruments Inc., Madison (WI, USA), 1994.

Etodolac (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic Acid): A Potent Antiinflammatory Drug. Conformation and Absolute Configuration of Its Active Enantiomer. L.G. Humber, C.A. Demerson, P. Swaminathan, P.H. Bird. J. Med. Chem. -1986. -29. –P. 871-874.